Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis

Pharmacotherapy

Volumn 30, Issue 1, 2010, Pages 95-108

  Prescott Jr , William A ^a   Nagel, Jerod L ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Aminoglycoside; Cystic fibrosis; EID; Extended interval dosing; Infectious disease; Once daily dosing; Pediatrics; Pharmacokinetics; Pulmonary exacerbations

Indexed keywords

AMIKACIN; CEFTAZIDIME; MEROPENEM; TOBRAMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; CHILD; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; OUTCOME ASSESSMENT; REVIEW; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; MIDDLE AGED; RESPIRATORY TRACT INFECTIONS; TOBRAMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75149158537     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.1.95     Document Type: Review

References (54)

1. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996;312:338-45.
2. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 2004;114:e111-18.
3. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997;39:677-86.
4. Pond MN, Newport M, Joanes D, Conway SP. Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis. Eur Respir J 1994;7:1640-4.
5. Rappaz I, Decosterd LA, Bille J, Pilet M, Belaz N, Roulet M. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr 2000;159:919-25.
6. Kraus DM, Pai MP, Rodvold KA. Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients. Paediatr Drugs 2002;4:469-84.
7. Taylor RF, Hodson ME. Cystic fibrosis: antibiotic prescribing practices in the United Kingdom and Eire. Respir Med 1993;87:535-9.
8. Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J 2002;19:303-9.
9. Powell SH, Thompson WL, Luthe MA, et al. Once-daily vs continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983;147:918-32.
10. Vic P, Ategbo S, Turck D, et al. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Eur J Pediatr 1996;155:948-53.
11. Master V, Roberts GW, Coulthard KP, et al. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Pediatr Pulmonol 2001;31:367-76.
12. Vic P, Ategbo S, Turck D, et al. Efficacy, tolerance, and pharmacokinetics of once-daily tobramycin for Pseudomonas exacerbations in cystic fibrosis. Arch Dis Child 1998;78:536-9.
13. Riethmueller J, Franke P, Schroeter TW, et al. Optimized intravenous antibiotic treatment with ceftazidime (thrice daily vs continuous) and tobramycin (thrice vs once daily) in CF patients. Presented at the 24th European cystic fibrosis conference, Vienna, Austria, June 6-9, 2001.
14. Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus threetimes daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis: the TOPIC study - a randomised controlled trial. Lancet 2005;365:573-8.
15. Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother 2006;58:822-9.
16. Smyth AR, Tan KH. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2006;(3):CD002009.
17. Schumock GT, Raber SR, Crawford SY, Naderer OJ, Rodvold KA. National survey of once-daily dosing of aminoglycoside antibiotics. Pharmacotherapy 1995;15:201-9.
18. Phillips JA, Bell SC. Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia. Intern Med J 2001;31:23-6.
19. Tan KH, Hyman-Tylor P, Mulheran M, Knox A, Smyth A. Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers [letter]. Pediatr Pulmonol 2002;33:165.
20. Cheong J, Jacklin A, Hodson M. The influence of the TOPIC study on the prescribing guidelines of aminoglycosides in cystic fibrosis units. Presented at the North American cystic fibrosis conference, Orlando, FL, October 23-25, 2008.
21. Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8.
22. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-47.
23. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991;27(suppl C):29-40.
24. Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande MA. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J Infect Dis 1988;158:7-12.
25. Bouvier d'Yvoire MJY, Maire PH. Dosage regimens of antibacterials: implications of a pharmacokinetic-pharmaco-dynamic model. Clin Drug Invest 1996;11:229-39.
26. Mouton JW, Jacobs N, Tiddens H, Horrevorts AM. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis 2005;52:123-7.
27. Demczar DJ, Nafziger AN, Bertino JS Jr. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother 1997;41:1115-19.
28. Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother 2000;44:809-13.
29. Bragonier R, Brown NM. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis. J Antimicrob Chemother 1998;42:103-6.
30. Lam W, Tjon J, Seto W, et al. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. J Antimicrob Chemother 2007;59:1135-40.
31. Tjon JA, Chan C, Murphy L, et al. Clinical evaluation of once-daily dosing tobramycin guidelines in paediatric patients with cystic fibrosis. Presented at the North American cystic fibrosis conference, Orlando, FL, October 23-25, 2008.
32. Chuck SK, Raber SR, Rodvold KA, Areff D. National survey of extended-interval aminoglycoside dosing. Clin Infect Dis 2000;30:433-9.
33. Bates RD, Nahata MC, Jones JW, et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest 1997;112:1208-13.
34. Beringer PM, Vinks AA, Jelliffe RW. Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis. J Antimicrob Chemother 1998;41:142-4.
35. Hamner JR, Poppy A, Ebaugh S, et al. Pharmacokinetics and safety of once-daily tobramycin in children with cystic fibrosis [abstract]. Pediatr Pulmonol 2006;41(S29):326.
36. Massie J, Cranswick N. Pharmacokinetic profile of once-daily intravenous tobramycin in children with cystic fibrosis. J Paediatr Child Health 2006;42:601-5.
37. Hennig S, Norris R, Kirkpatrick CM. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis: a population pharmacokinetic study. Br J Clin Pharmacol 2008;65:502-10.
38. Slagter R, Alffenaar J, Duiverman E, Uges D, Rottier B. IV tobramycin in pediatric CF patients: once or twice daily. Presented at the North American cystic fibrosis conference, Orlando, FL, October 23-25, 2008.
39. Canis F, Husson MO, Turck D, et al. Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients. J Antimicrob Chemother 1997;39:431-3.
40. Byl B, Baran D, Jacobs F, Herschuelz A, Thys JP. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients. J Antimicrob Chemother 2001;48:325-7.
41. Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J Cyst Fibros 2007;6:327-33.
42. Guglielmo BJ, Quan LA, Stulbarg MS. Pharmacokinetics of once-daily versus thrice-daily tobramycin in cystic fibrosis patients. J Antimicrob Chemother 1996;37:1040-2.
43. Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother 2002;50:553-9.
44. Swan SK. Aminoglycoside nephrotoxicity. Semin Nephrol 1997;17:27-33.
45. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999;43:1003-12.
46. Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother 1989;33:797-800.
47. Fischel-Ghodsian N, Prezant TR, Chaltraw WE, et al. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Am J Otolaryngol 1997;18:173-8.
48. Bitner-Glindzicz M, Rahman S. Ototoxicity caused by aminoglycosides. BMJ 2007;335:784-5.
49. Phillips J, Nelson L, Kramer J, Wilson M, Lang S. Twelve-hour pharmacokinetics and ototoxicity of tobramycin in CF [abstract]. Pediatr Pulmonol 1993;9:263.
50. Mulheran M, Hyman-Taylor P, Tan KH, et al. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients. Antimicrob Agents Chemother 2006;50:2293-9.
51. Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J. Therapeutic drug monitoring of once-daily tobramycin in cystic fibrosis: caution with trough concentrations. J Cyst Fibros 2007;6:125-30.
52. van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monitor 1999;21:63-73.
53. Touw DJ, Vinks AA, Heijerman HG, Bakker W. Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis. Ther Drug Monit 1993;15:52-9.
54. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995;39:650-5.